# Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma

> **NCT00518206** · PHASE2 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 46 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** NY-ESO-1 ISCOMATRIX® vaccine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00518206
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11-28
- **Primary completion:** 2010-01-22
- **Final completion:** 2010-01-22
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-10-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00518206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00518206, "Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00518206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*